proxyvotesnow.com

Home › Companies › KEROS THERAPEUTICS INC. › 2023-2024

KEROS THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and KEROS THERAPEUTICS INC.’s Form 8-K, filed 2024-05-30 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 11Reported items
  • 165Asset managers
  • 1,527Fund votes
  • 2024-05-30Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore KEROS THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by KEROS THERAPEUTICS INC.

These tallies are KEROS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-30 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

KEROS THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-05-30
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Jasbir Seehra, Ph.D. 28,980,411---- 199,9243,109,658 Majority: yes
Elect Director: Nima Farzan 22,751,167---- 6,429,1683,109,658 Majority: yes
Elect Director: Julius Knowles 21,464,815---- 7,715,5203,109,658 Majority: yes
Proposal 2: Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2024 The Company's stockholders appr 32,276,7681,43914 ---- Majority: yes
Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3 28,988,355183,2678,066 --3,098,533 Majority: yes

Source: KEROS THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-05-30 — read the filing on EDGAR.

How asset managers voted at the KEROS THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 165 asset managers that disclosed a KEROS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of KEROS THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 28,988,355AGAINST: 183,267

KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 28,988,355 for, 183,267 against, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 80% for, 0.6% against (81% of the company cast a for/against vote).

The 157 asset managers below cast 99.6% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 99.6%
FOR: 99.7%AGAINST: 0.3%
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in t” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
New York Life18,000,0000 00For
Fidelity10,242,7080 00For
State Street2,346,8530 00For
T. Rowe Price2,122,7880 00For
BlackRock1,544,8900 00For
Vanguard1,544,7580 00For
Point72976,9810 00For
TCG Crossover Management, LLC879,3440 00For
Woodline Partners LP701,9990 00For
MUTUAL FUND SERIES TRUST680,0000 00For
Candriam S.C.A.651,9810 00For
FRANKLIN ADVISERS INC619,6090 00For
GEODE CAPITAL MANAGEMENT, LLC597,6630 00For
ALKEON CAPITAL MANAGEMENT LLC580,9200 00For
BRAIDWELL LP568,7650 00For
Redmile Group, LLC552,5060 00For
American Century419,3160 00For
Charles Schwab415,5160 00For
ORBIMED ADVISORS LLC375,2000 00For
Soleus Capital Management, L.P.273,6000 00For
Northern Trust234,70015 00For
Advantage Advisers Xanthus Fund, L.L.C.228,8890 00For
FRANKLIN STRATEGIC SERIES214,3500 00For
EcoR1 Capital, LLC187,5000 00For
Avidity Partners Management LP125,5590 00For

Showing the 25 largest of 157 asset managers. See all 157 in the interactive database.

2. To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 95%

The 128 asset managers below cast 100% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR: 1.5%ONE YEAR: 95.0%1 YEAR: 3.1%THREE YEARS: 0.3%1-YEAR: 0.1%3 YEARS: 0.0%
Largest asset managers voting on “To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation o” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
New York Life00 00One Year
Fidelity00 00One Year
State Street00 00One Year
T. Rowe Price00 00One Year
BlackRock00 00One Year
Vanguard00 00One Year
Point7200 00One Year
Woodline Partners LP00 00One Year
MUTUAL FUND SERIES TRUST680,0000 00For
Candriam S.C.A.00 00One Year
FRANKLIN ADVISERS INC00 00One Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
ALKEON CAPITAL MANAGEMENT LLC00 00One Year
BRAIDWELL LP00 00One Year
American Century00 00One Year
ORBIMED ADVISORS LLC00 001 Year
Soleus Capital Management, L.P.00 001 Year
Northern Trust00 001 Year
Advantage Advisers Xanthus Fund, L.L.C.00 00One Year
FRANKLIN STRATEGIC SERIES00 00One Year
Dimensional00 00Three Years
Nuveen00 00One Year
Granahan Investment Management, LLC00 001 Year
Jackson National00 001 Year
WCM INVESTMENT MANAGEMENT, LLC00 001 Year

Showing the 25 largest of 128 asset managers. See all 128 in the interactive database.

3. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 32,276,768AGAINST: 1,439

KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December ”): 32,276,768 for, 1,439 against, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 89% for, 0.1% against (89% of the company cast a for/against vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (11,863,468 for, 0 against).

FOR 100%
FOR: 11,863,468 (100.0%)
Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the indep” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,224,5560 00For
Vanguard1,473,7450 00For
State Street932,8730 00For
T. Rowe Price932,3090 00For
BlackRock896,9860 00For
MUTUAL FUND SERIES TRUST680,0000 00For
Advantage Advisers Xanthus Fund, L.L.C.228,8890 00For
FRANKLIN STRATEGIC SERIES214,3500 00For
Charles Schwab207,7580 00For
American Century206,0400 00For
Dimensional91,0330 00For
Jackson National87,2510 00For
Direxion Shares ETF Trust81,6130 00For
TIAA73,8480 00For
Equitable61,5860 00For
Russell Investments56,9570 00For
QUANTITATIVE MASTER SERIES LLC42,5980 00For
Victory Capital30,5120 00For
Nushares ETF Trust26,2290 00For
ALGER FUNDS26,2080 00For
ProShares25,7970 00For
ALPS ETF Trust25,3780 00For
Lincoln Financial19,3770 00For
Tema ETF Trust13,9480 00For
Northern Trust13,7670 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

4. To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Jasbir Seehra

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 28,980,411WITHHELD: 199,924

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jasbir Seehra, Ph.D.”): 28,980,411 for, 199,924 withheld, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 80% for, 0.6% withheld (81% of the company cast a for/withheld vote).

The 62 asset managers below cast 100% of the shares they voted on this item FOR (11,757,522 for, 0 against).

FOR 99.1%
FOR: 11,757,522 (99.2%)ABSTAIN: 95,841 (0.8%)
Largest asset managers voting on “To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stock” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,224,5560 00For
Vanguard1,473,7450 00For
State Street931,8310 1,0420For
T. Rowe Price932,3090 00For
BlackRock896,9860 00For
MUTUAL FUND SERIES TRUST680,0000 00For
Advantage Advisers Xanthus Fund, L.L.C.228,8890 00For
FRANKLIN STRATEGIC SERIES214,3500 00For
Charles Schwab207,7580 00For
American Century206,0400 00For
Dimensional00 91,0330Abstain
Jackson National84,5750 2,6760For
Direxion Shares ETF Trust81,6130 00For
TIAA73,8480 00For
Equitable61,5860 00For
Russell Investments56,9570 00For
QUANTITATIVE MASTER SERIES LLC42,5980 00For
Victory Capital30,5120 00For
Nushares ETF Trust26,2290 00For
ALGER FUNDS26,2080 00For
ProShares25,7970 00For
ALPS ETF Trust25,3780 00For
Lincoln Financial18,9000 4770For
Tema ETF Trust13,9480 00For
Northern Trust13,7670 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

5. To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Julius Knowles

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%
FOR: 21,464,815WITHHELD: 7,715,520

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Julius Knowles”): 21,464,815 for, 7,715,520 withheld, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 60% for, 21% withheld (81% of the company cast a for/withheld vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (9,806,136 for, 29 against).

FOR 83%ABSTAIN 17%
FOR: 9,806,136 (82.7%)AGAINST: 29 (0.0%)ABSTAIN: 2,047,198 (17.3%)
Largest asset managers voting on “To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stock” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,224,5560 00For
Vanguard1,473,7450 00For
State Street10,0440 922,8290Abstain
T. Rowe Price932,3090 00For
BlackRock896,9860 00For
MUTUAL FUND SERIES TRUST680,0000 00For
Advantage Advisers Xanthus Fund, L.L.C.00 228,8890Abstain
FRANKLIN STRATEGIC SERIES00 214,3500Abstain
Charles Schwab207,7580 00For
American Century00 206,0400Abstain
Dimensional00 91,0330Abstain
Jackson National65,2900 21,9610For
Direxion Shares ETF Trust00 81,6130Abstain
TIAA73,8480 00For
Equitable39,0860 22,5000For
Russell Investments56,9570 00For
QUANTITATIVE MASTER SERIES LLC42,5980 00For
Victory Capital00 30,5120Abstain
Nushares ETF Trust26,2290 00For
ALGER FUNDS00 26,2080Abstain
ProShares00 25,7970Abstain
ALPS ETF Trust00 25,3780Abstain
Lincoln Financial00 19,3770Abstain
Tema ETF Trust13,9480 00For
Northern Trust13,7670 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

6. To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stockholders: Nima Farzan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%
FOR: 22,751,167WITHHELD: 6,429,168

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nima Farzan”): 22,751,167 for, 6,429,168 withheld, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 63% for, 18% withheld (81% of the company cast a for/withheld vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (10,965,145 for, 29 against).

FOR 93%7%
FOR: 10,965,145 (92.5%)AGAINST: 29 (0.0%)ABSTAIN: 888,189 (7.5%)
Largest asset managers voting on “To elect the three (3) nominees for director named below to hold office until the 2027 Annual Meeting of Stock” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity5,224,5560 00For
Vanguard1,473,7450 00For
State Street919,3610 13,5120For
T. Rowe Price932,3090 00For
BlackRock896,9860 00For
MUTUAL FUND SERIES TRUST680,0000 00For
Advantage Advisers Xanthus Fund, L.L.C.00 228,8890Abstain
FRANKLIN STRATEGIC SERIES214,3500 00For
Charles Schwab207,7580 00For
American Century00 206,0400Abstain
Dimensional00 91,0330Abstain
Jackson National65,2900 21,9610For
Direxion Shares ETF Trust00 81,6130Abstain
TIAA73,8480 00For
Equitable39,0860 22,5000For
Russell Investments56,9570 00For
QUANTITATIVE MASTER SERIES LLC42,5980 00For
Victory Capital00 30,5120Abstain
Nushares ETF Trust26,2290 00For
ALGER FUNDS00 26,2080Abstain
ProShares00 25,7970Abstain
ALPS ETF Trust00 25,3780Abstain
Lincoln Financial18,9000 4770For
Tema ETF Trust13,9480 00For
Northern Trust13,7670 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

7. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company s named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

— fund support · no official result

1 YEAR 61%ONE YEAR 39%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 1,356,317 (60.7%)ONE YEAR: 879,540 (39.3%)
Largest asset managers voting on “To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation o” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TCG Crossover Management, LLC00 00One Year
Redmile Group, LLC00 001 Year
Charles Schwab00 001 Year
Avidity Partners Management LP00 001 Year
Russell Investments00 001 Year
DAFNA Capital Management LLC00 001 Year
PLATINUM INVESTMENT MANAGEMENT LTD00 001 Year
Putnam00 001 Year
NEW YORK STATE COMMON RETIREMENT FUND00 001 Year
Global X00 001 Year
SEI00 001 Year
Arizona State Retirement System00 001 Year
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM00 001 Year
MARSHALL WACE, LLP00 001 Year
Investment Managers Series Trust00 001 Year
BANK OF AMERICA NA00 001 Year
Prudential/PGIM00 001 Year
MACKENZIE FINANCIAL CORP00 001 Year
UNITED CAPITAL FINANCIAL ADVISORS, LLC00 001 Year
Neuberger Berman00 001 Year
YOUSIF CAPITAL MANAGEMENT, LLC00 001 Year
OREGON PUBLIC EMPLOYEES RETIREMENT FUND00 001 Year
Nationwide00 00One Year
Vestmark Advisory Solutions, Inc.00 001 Year
Daiwa Securities Group Inc.00 001 Year

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1-YEAR 95%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1-YEAR: 190,000 (95.1%)ONE YEAR: 9,753 (4.9%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.00 001-Year
JPMorgan00 00One Year
Desjardins Global Asset Management Inc.00 00One Year

9. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 28,988,355AGAINST: 183,267

KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 28,988,355 for, 183,267 against, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 80% for, 0.6% against (81% of the company cast a for/against vote).

The 3 asset managers below cast 99.8% of the shares they voted on this item FOR (199,372 for, 381 against).

FOR 99.8%
FOR: 199,372 (99.8%)AGAINST: 381 (0.2%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.190,0000 00For
JPMorgan9,3720 00For
Desjardins Global Asset Management Inc.0381 00Against

10. To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 28,988,355AGAINST: 183,267

KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 28,988,355 for, 183,267 against, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 80% for, 0.6% against (81% of the company cast a for/against vote).

The 3 asset managers below cast 100% of the shares they voted on this item FOR (1,108,650 for, 0 against).

FOR 100%
FOR: 1,108,650 (100.0%)
Largest asset managers voting on “To approve on an advisory (non-binding) basis the compensation of the Company's named executive officers.” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ORBIMED ADVISORS LLC893,5340 00For
Integral Health Asset Management, LLC205,0110 00For
EDBI Pte Ltd10,1050 00For

11. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 28,988,355AGAINST: 183,267

KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 28,988,355 for, 183,267 against, per its Form 8-K filed 2024-05-30 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 36,067,786 outstanding shares: 80% for, 0.6% against (81% of the company cast a for/against vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (360,000 for, 0 against).

FOR 100%
FOR: 360,000 (100.0%)
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in t” at KEROS THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Opaleye Management Inc.360,0000 00For
AMERICAN FINANCIAL GROUP INC00 00--

Largest KEROS THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of KEROS THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 36,067,786 shares outstanding at the time of that meeting.

Top KEROS THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1New York Life 49.91%
2Fidelity 28.40%
3State Street 6.51%
4T. Rowe Price 5.89%
5BlackRock 4.28%
6Vanguard 4.28%
7Point72 2.71%
8TCG Crossover Management, LLC 2.44%
9Woodline Partners LP 1.95%
10MUTUAL FUND SERIES TRUST 1.89%

Reported KEROS THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

KEROS THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Ran Nussbaum 13.35% DEF14A
Tomer Kariv 13.35% DEF14A
Entities affiliated with Pontifax 13.27% DEF14A
FMR LLC 10.74% DEF14A
Vanguard Group 7.54% 13F
BlackRock 7.53% 13F
Jasbir Seehra, Ph.D. 4.34% DEF14A
State Street 4.33% 13F
Goldman Sachs 3.67% 13F
Carl L. Gordon, Ph.D., C.F.A. 3.59% DEF14A

Percentages above are of 36,067,786 shares outstanding, as reported by KEROS THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KEROS THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At KEROS THERAPEUTICS INC.'s shareholder meeting held 2024-05-30, in the 2023-2024 proxy season, 165 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,527 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers as… — FOR was 99.3% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KEROS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-30.

KEROS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.